Antithrombotic therapy for prevention and treatment of ischemic stroke

被引：6

作者：

Albers, GW

机构：

[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA

[2] Stanford Stroke Ctr, Palo Alto, CA USA

来源：

JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 2001年 / 12卷 / 01期

关键词：

stroke; ischemia; anticoagulation; tPA;

D O I：

10.1023/A:1012709309064

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Atherosclerosis involving the cervical vessels, intracranial vessels, or the aorta is the most common cause of ischemic stroke. Occlusive lesions of small penetrating brain arteries cause small "lacunar" strokes, which account for about 20% of ischemic strokes. Emboli from a variety of cardiac sources, particularly atrial fibrillation, account for about 25%. Efforts to prevent and treat ischemic stroke are complicated by the variety of etiologies underlying it and the selection of antithrombotic or thrombolytic therapy appropriate to the particular etiology.

引用

页码：19 / 22

页数：4

共 14 条

[1] Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke - A randomized controlled trial [J].

Adams, HP ;

Woolson, RF ;

Helgason, C ;

Karanjia, PN ;

Gordon, DL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (16) :1265-1272

[2] Antithrombotic and thrombolytic therapy for ischemic stroke [J].

Albers, CW ;

Amarenco, P ;

Easton, JD ;

Sacco, RL ;

Teal, P .

CHEST, 2001, 119 (01) :300S-320S

[3] Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study [J].

Albers, GW ;

Bates, VE ;

Clark, WM ;

Bell, R ;

Verro, P ;

Hamilton, SA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1145-1150

[4] Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia [J].

Algra, A ;

vanGijn, J .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 60 (02) :197-199

[5] CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke [J].

Chen, ZM ;

Hui, JM ;

Liu, LS ;

Liu, ZM ;

Peto, R ;

Sandercock, P ;

Wang, WQ ;

Wang, YX ;

Wang, ZB ;

Xie, JX ;

You, GX ;

Zhang, FL ;

Zhang, HQ ;

Zhao, ZY .

LANCET, 1997, 349 (9066) :1641-1649

[6] Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].

Clark, WM ;

Wissman, S ;

Albers, GW ;

Jhamandas, JH ;

Madden, KP ;

Hamilton, S .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026

[7] Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial [J].

Furlan, A ;

Higashida, R ;

Wechsler, L ;

Gent, M ;

Rowley, H ;

Kase, C ;

Pessin, M ;

Ahuja, A ;

Callahan, F ;

Clark, WM ;

Silver, F ;

Rivera, F .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2003-2011

[8] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].

Hacke, W ;

Kaste, M ;

Fieschi, C ;

von Kummer, R ;

Davalos, A ;

Meier, D ;

Larrue, V ;

Bluhmki, E ;

Davis, S ;

Donnan, G ;

Schneider, D ;

Diez-Tejedor, E ;

Trouillas, P .

LANCET, 1998, 352 (9136) :1245-1251

[9]

HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017

[10]

KOUDSTAAL PJ, 1993, LANCET, V342, P1255

← 1 2 →